LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Closed

2.72 2.64

Overview

Share price change

24h

Current

Min

2.6

Max

2.72

Key metrics

By Trading Economics

Income

-17M

-70M

Sales

547K

47M

Profit margin

-147.345

Employees

560

EBITDA

-17M

-66M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+74.91% upside

Dividends

By Dow Jones

Next Earnings

6 lis 2025

Market Stats

By TradingEconomics

Market Cap

166M

919M

Previous open

0.08

Previous close

2.72

Technical Score

By Trading Central

Confidence

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 wrz 2025, 22:39 UTC

Acquisitions, Mergers, Takeovers

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15 wrz 2025, 16:43 UTC

Major Market Movers

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15 wrz 2025, 16:42 UTC

Major Market Movers

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15 wrz 2025, 16:35 UTC

Major Market Movers

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15 wrz 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 wrz 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15 wrz 2025, 23:34 UTC

Market Talk

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15 wrz 2025, 22:48 UTC

Market Talk

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15 wrz 2025, 22:12 UTC

Acquisitions, Mergers, Takeovers

CSL Expects Commercial Launch in 2029

15 wrz 2025, 22:12 UTC

Acquisitions, Mergers, Takeovers

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15 wrz 2025, 22:11 UTC

Acquisitions, Mergers, Takeovers

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15 wrz 2025, 22:11 UTC

Acquisitions, Mergers, Takeovers

CSL to Have Right to Exercise Option Based on Phase 3 Data

15 wrz 2025, 22:10 UTC

Acquisitions, Mergers, Takeovers

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15 wrz 2025, 21:16 UTC

Acquisitions, Mergers, Takeovers

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15 wrz 2025, 21:16 UTC

Acquisitions, Mergers, Takeovers

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15 wrz 2025, 21:15 UTC

Acquisitions, Mergers, Takeovers

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15 wrz 2025, 21:14 UTC

Acquisitions, Mergers, Takeovers

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15 wrz 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 wrz 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15 wrz 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 wrz 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15 wrz 2025, 19:14 UTC

Market Talk

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15 wrz 2025, 18:16 UTC

Market Talk

Gold Powers to New High -- Market Talk

15 wrz 2025, 18:05 UTC

Market Talk

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15 wrz 2025, 17:50 UTC

Acquisitions, Mergers, Takeovers

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15 wrz 2025, 17:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 wrz 2025, 17:10 UTC

Market Talk

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15 wrz 2025, 16:52 UTC

Market Talk

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15 wrz 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

15 wrz 2025, 16:20 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

Peer Comparison

Price change

Maravai LifeSciences Holdings Inc (Class A) Forecast

Price Target

By TipRanks

74.91% upside

12 Months Forecast

Average 4.67 USD  74.91%

High 5 USD

Low 4 USD

Based on 6 Wall Street analysts offering 12 month price targets forMaravai LifeSciences Holdings Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

4

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

2.02 / 2.115Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

No Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat